SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant attention as its patented Optical Interposer platform is seen as crucial for next-generation AI and data center infrastructure, enabling highly efficient and scalable optical interconnects. The community is actively discussing recent product innovation awards and confirmed partnerships, including with Celestial AI (now Marvell), which validate its technology. Anticipation is also building for the imminent disclosure of major institutional investors, signaling strong long-term confidence.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Fueled Inspire Veterinary Partners' (IVP) 27% After-Hours Rally?

Inspire Veterinary Partners shares jumped 27% after the company announced a consulting agreement issuing 9.45 million shares to 622 Capital.read more...

Zacks Initiates Coverage of Inspire Veterinary With Underperform Recommendation

Find out why Zacks assigns an "Underperform" rating to Inspire Veterinary, being the first on Wall Street to initiate coverage on the stock. Explore how steep losses, funding risks, and weak revenue trends challenge its ambitious expansion and new digital ventures.

<ul class="summary-bullets"><li>Inspire Veterinary Partners has received a formal warning from Nasdaq’s Listing Qualifications Department.</li><li>Inspire is ineligible for any cure period because of its reverse stock splits totaling a ratio of 250-to-1.</li><li>For the third-quarter, the company’s revenue rose by 7% year-on-year.</li></ul>Inspire Veterinary Partners (IVP) stock gained spotlight on Monday amid a potential delisting possibility after receiving a formal warning from Nasdaq’s Listing Qualifications Department.Inspire Veterinary Partners owns and operates animal care clinics across the United States.<h2 class="st-heading-2">Nasdaq Warning</h2>On Nov, 13, 2025, the company was notified that its common stock failed to maintain the required minimum bid price over 30 consecutive business days, putting it in violation of the Nasdaq Listing Rule.&nbsp;The notice also cited that Inspire is ineligible for any cure period because it has carried out reverse stock splits totaling a ratio of 250-to-1 or more over the past two years.<a href="https://stocktwits.com/symbol/IVP">Inspire Veterinary Partners’ stock</a> traded over 52% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h2 class="st-heading-2">Risk of Suspension</h2>The notification said that unless Inspire appeals to Nasdaq’s Hearings Panel by Nov. 20, 2025, its shares may be suspended from trading beginning Nov. 24, 2025.&nbsp;Earlier in 2025, Inspire completed a 1-for-25 reverse stock split, a move likely made to help lift its share price above the minimum threshold. The company has also carried out a prior 1-for-100 split in May 2024.&nbsp;For the third quarter, the company’s revenue rose by 7% year-on-year (YoY) to $4.3 million, net losses fell by 27% YoY, and revenue at comparable clinics grew 9.2% YoY.In October, Inspire Veterinary announced the launch of an online pet pharmacy to give veterinarians and pet owners access to a wide range of prescription and over-the-counter pet care products.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/quantum-enabled-drones-ion-q-and-heven-forge-defense-alliance/cL5b7ASREQI">Quantum-Enabled Drones: IonQ And Heven Forge Defense Alliance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A German Shepherd, which San Francisco Animal Care and Control suspect was used as bait in pit bull fights, is assisted in lying down by Debbie Utter, veterinary technician.

Why Is IVP Stock Drawing Investor Attention Today?

Inspire Veterinary Partners has received a formal warning from Nasdaq’s Listing Qualifications Department.

Equity

On Nov. 13, 2025, the company was notified that its common stock failed to maintain the required minimum bid price.


Inspire Veterinary Partners, Inc. engages in the business of operating small animal general practice hospitals which serve all manner of companion pets, emphasizing canine, and feline breeds and including equine care. The firm is also involved in acquiring additional veterinary hospitals including general practice, mixed animal facilities, and critical and emergency care. The company was founded on December 2, 2020 and is headquartered in Virginia Beach, VA.

Current Price	$0.0405
Prev Close	$0.05
Open	$0.045
Dividend Yield	0.00%
50-Day Moving Average	$0.1911
Beta	1.29
Avg. Volume	58.32M
PE Ratio	-0.01

52-Week High	$4.12
52-Week Low	$0.0225
Market Capitalization	$1.68M
EPS (Annual)	-$2.61
Price to Book	0.06
Revenue Per Employee	$146,832.82
Enterprise Value/EBITDA	N/A

IVP
Inspire Veterinary Partners Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest IVP News

IVPInspire Veterinary Partners Inc. - Ordinary Shares - Class A